the tivo-3 study of tivozanib in metastatic renal cell carcinoma
Published 4 years ago • 552 plays • Length 12:49Download video MP4
Download video MP3
Similar videos
-
1:28
dr. motzer on the tivo-3 trial examining tivozanib in advanced rcc
-
2:42
latest from tivo-3: tivozanib for refractory advanced renal cell carcinoma
-
7:22
long-term benefits of tivozanib: insights from the tivo-3 study
-
0:52
dr. pal on the rationale for the tivo-3 trial with tivozanib in advanced rcc
-
1:24
dr. motzer on the tivo-1 trial with tivozanib in advanced rcc
-
3:38
t-cell activation
-
10:48
how the immune system actually works – immune
-
11:46
you are immune against every disease
-
1:05
dr. pal on potential tivozanib-based combinations in rcc
-
4:42
asco: tivozanib for metastatic renal cell carcinoma
-
4:07
tivo-3 results point to tivozanib activity after rcc progression on axitinib | brian rini
-
0:59
data support use of tivozanib in patients with advanced renal cell carcinoma
-
1:15
dr. vaishampayan on the safety of tivozanib versus sorafenib in rcc
-
1:00
dr. vaishampayan on the potential of tivozanib in advanced rcc
-
1:44
tivo-3: tivozanib hydrochloride vs sorafenib for refractory advanced rcc
-
2:07
dr. subbiah on the importance of tivozanib in rcc
-
1:41
tivozanib tolerability shows potential advantage for patients with advanced rcc
-
1:57
dr. mayer on tivozanib in renal cell carcinoma and breast cancer
-
0:50
dr. pal on the benefit of tivozanib in later-line settings for refractory rcc
-
0:33
rana mckay, md, offers impressions of the tivo-3 study in highly refractory advanced rcc patients
-
2:06
dr. rini discusses tivozanib in advanced rcc
-
1:20
tivozanib